{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:55:21Z","timestamp":1790625321085,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Anthracycline chemotherapy is associated with cardiotoxicity, underscoring the importance of minimizing modifiable cardiac risk factors in affected individuals. This study evaluated cardiac function, prevalence of metabolic syndrome and smoking, and awareness of prior cardiotoxic treatment among adult survivors of childhood cancer treated with anthracyclines at the pediatric oncology service in Iceland between 1981 and 2011 (n=89). Data were collected from medical records, self-reported questionnaires, and clinical assessments conducted between 2016 and 2019. Of 76 eligible survivors, 60 participated (29 females, 31 males; aged 20 to 48\u00a0y). Two individuals were excluded before enrollment due to previously diagnosed heart failure. Left ventricular dilation was observed in 15 participants (25%), predominantly mild to moderate, with 1 severe case. The prevalence was lower after BSA indexing. Metabolic syndrome was present in 20% of participants, and 20% reported current smoking. Approximately half of the participants reported undergoing echocardiography within the past 10 years, while only 10% were aware that their cancer treatment could cause cardiotoxicity. These findings suggest that survivors treated with anthracyclines require systematic surveillance and targeted interventions to address modifiable cardiovascular risk factors. Increasing awareness of prior cardiotoxic cancer treatment among survivors and health care providers may facilitate cardiovascular risk reduction.<\/jats:p>","DOI":"10.1097\/mph.0000000000003245","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:00:14Z","timestamp":1785355214000},"page":"e299-e307","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cardiometabolic Risk and Awareness of Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer: A Population-Based Study"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2902-6312","authenticated-orcid":false,"given":"Vigd\u00eds H.","family":"Vigg\u00f3sd\u00f3ttir","sequence":"first","affiliation":[{"name":"Faculty of Nursing and Midwifery"},{"name":"Department of Pediatrics, Landspitali\u2014University Hospital, Reykjav\u00edk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hr\u00f3\u00f0mar","family":"Helgason","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Landspitali\u2014University Hospital, Reykjav\u00edk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-869X","authenticated-orcid":false,"given":"Helga","family":"J\u00f3nsd\u00f3ttir","sequence":"additional","affiliation":[{"name":"Faculty of Nursing and Midwifery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7998-5433","authenticated-orcid":false,"given":"Thor","family":"Aspelund","sequence":"additional","affiliation":[{"name":"Centre of Public Health Sciences, University of Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-9689","authenticated-orcid":false,"given":"Ragnar","family":"Bjarnason","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Faculty, School of Health Sciences"},{"name":"Department of Pediatrics, Landspitali\u2014University Hospital, Reykjav\u00edk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-5366","authenticated-orcid":false,"given":"Marianne","family":"Jarfelt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg"},{"name":"The Long-Term Follow-Up Clinic for Childhood Cancer Survivors at Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"R1-20260928","doi-asserted-by":"crossref","first-page":"21","DOI":"10.17992\/lbl.2010.01.04","article-title":"Childhood cancer in Iceland 1981\u20132006 [in Icelandic]","volume":"96","author":"\u00d3skarsson","year":"2010","journal-title":"L\u00e6knabla\u00f0i\u00f0"},{"key":"R3-20260928","doi-asserted-by":"crossref","first-page":"675","DOI":"10.17992\/lbl.2010.11.325","article-title":"Survival and causes of death in children diagnosed with cancer in Iceland 1981\u20132006 [in Icelandic]","volume":"96","author":"\u00d3skarsson","year":"2010","journal-title":"L\u00e6knabla\u00f0i\u00f0"},{"key":"R4-20260928","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-20260928","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","article-title":"Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study","volume":"32","author":"Armstrong","year":"2014","journal-title":"J Clin Oncol"},{"key":"R6-20260928","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/tx500374k","article-title":"Impact of cancer therapy-related exposures on late mortality in childhood cancer survivors","volume":"28","author":"Gibson","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"R7-20260928","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","article-title":"Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study","volume":"27","author":"Armstrong","year":"2009","journal-title":"J Clin Oncol"},{"key":"R8-20260928","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/leu.2009.253","article-title":"Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985\u20132000)","volume":"24","author":"Silverman","year":"2010","journal-title":"Leukemia"},{"key":"R9-20260928","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"key":"R10-20260928","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1470-2045(23)00012-8","article-title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"24","author":"Ehrhardt","year":"2023","journal-title":"Lancet Oncol"},{"key":"R11-20260928","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/pbc.21289","article-title":"Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia","volume":"49","author":"Jarfelt","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20260928","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00431-016-2776-9","article-title":"Speckle tracking echocardiography detects decreased cardiac longitudinal function in anthracycline-exposed survivors of childhood cancer","volume":"175","author":"Yl\u00e4nen","year":"2016","journal-title":"Eur J Pediatr"},{"key":"R13-20260928","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1158\/1055-9965.EPI-20-0809","article-title":"Cardiovascular family history increases risk for late-onset adverse cardiovascular outcomes in childhood cancer survivors: a St. Jude Lifetime Cohort report","volume":"30","author":"Goldberg","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R14-20260928","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12350-015-0309-y","article-title":"Assessment of late anthracycline-induced cardiotoxicity by 123I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence","volume":"24","author":"dos Santos","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"R15-20260928","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R16-20260928","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/jpm12060880","article-title":"Biomarkers predictive of metabolic syndrome and cardiovascular disease in childhood cancer survivors","volume":"12","author":"Romano","year":"2022","journal-title":"J Pers Med"},{"key":"R17-20260928","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.canep.2016.01.009","article-title":"Health conditions associated with metabolic syndrome after cancer at a young age: a nationwide register-based study","volume":"41","author":"Kero","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"R18-20260928","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2018.10.010","article-title":"Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors","volume":"133","author":"Pluimakers","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"R19-20260928","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"R20-20260928","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"R21-20260928","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R22-20260928","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERP-19-0050","article-title":"Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: a guideline from the British Society of Echocardiography","volume":"7","author":"Harkness","year":"2020","journal-title":"Echo Res Pract"},{"key":"R23-20260928","first-page":"19","article-title":"New Echocardiography Reference Ranges for Aotearoa (NewERA) Study: the application of international echocardiographic reference values to linear measurements of the hearts of healthy, young M\u0101ori and Pacific adults may not detect cardiac enlargement","volume":"135","author":"Whalley","year":"2022","journal-title":"N Z Med J"},{"key":"R25-20260928","first-page":"533","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography and for heart failure with preserved ejection fraction diagnosis: an update from the American Society of Echocardiography","volume":"38","author":"Nagueh","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"R26-20260928","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/HYPERTENSIONAHA.124.24173","article-title":"What is new and different in the 2024 European Society of Cardiology guidelines for the management of elevated blood pressure and hypertension?","volume":"82","author":"McCarthy","year":"2025","journal-title":"Hypertension"},{"key":"R30-20260928","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome\u2014a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"R31-20260928","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(24)00157-8","article-title":"The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study","volume":"25","author":"Hammoud","year":"2024","journal-title":"Lancet Oncol"},{"key":"R32-20260928","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2340\/1651-226X.2025.43654","article-title":"Heart failure in long-term survivors of childhood cancer\u2014a systematic review and meta-analysis of population-based studies","volume":"64","author":"Berg","year":"2025","journal-title":"Acta Oncol"},{"key":"R34-20260928","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11764-015-0482-7","article-title":"Factors associated with childhood cancer survivors\u2019 knowledge about their diagnosis, treatment, and risk for late effects","volume":"10","author":"Syed","year":"2016","journal-title":"J Cancer Surviv"},{"key":"R35-20260928","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11764-013-0291-9","article-title":"Attendance at a survivorship clinic: impact on knowledge and psychosocial adjustment","volume":"7","author":"Ford","year":"2013","journal-title":"J Cancer Surviv"},{"key":"R36-20260928","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jpepsy\/jsy102","article-title":"Knowledge of late effects risks and healthcare responsibility in adolescents and young adults treated for childhood cancer","volume":"44","author":"Lee","year":"2019","journal-title":"J Pediatr Psychol"},{"key":"R37-20260928","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2017.76.3268","article-title":"Endocrine late effects in childhood cancer survivors","volume":"36","author":"Chemaitilly","year":"2018","journal-title":"J Clin Oncol"},{"key":"R38-20260928","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000495698","article-title":"Diabetes and metabolic syndrome in survivors of childhood cancer","volume":"91","author":"Friedman","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"R40-20260928","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1093\/ejendo\/lvaf046","article-title":"Metabolic syndrome in childhood, adolescent, and young adult cancer survivors: recommendations for surveillance from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"192","author":"van den Oever","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"R45-20260928","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/pbc.23139","article-title":"Risk factors for smoking among adolescent survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"58","author":"Kahalley","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R46-20260928","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1200\/JCO.19.01825","article-title":"Adherence to surveillance for second malignant neoplasms and cardiac dysfunction in childhood cancer survivors: a Childhood Cancer Survivor Study","volume":"38","author":"Yan","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:17Z","timestamp":1790622017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003245","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"2025-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}